The Filtrate welcome Drs. Anna Burgner and George Bakris to discuss the breakthrough clinical trial FIDELIO and the non-steroidal aldosteropne antagonist, finerenone.
Visual abstract for FIDELIO
Beautiful visual abstract by Dhwanil Patel
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
The Filtrate welcome Drs. Anna Burgner and George Bakris to discuss the breakthrough clinical trial FIDELIO and the non-steroidal aldosteropne antagonist, finerenone.
Beautiful visual abstract by Dhwanil Patel